BiotechMarch 26, 2026

Biotech Thursday: Gene Editors at Multi-Year Lows, Loaded Runways, and Insider Buys

Top 5 Pixie Picks

This Week's Setup

This week's biotech screen rewards clinical density and balance-sheet runway more than sector averages. ARDX pairs IBSRELA growth with a six-year cash runway, BEAM advances base editing with NEJM-backed data and insider accumulation, and CRSP keeps the first approved CRISPR therapy in the mix while the market prices trial noise.

The rest of the list stacks rare disease revenue, oncology franchises, and platform dilution risk in ways that only show up when you read trial counts, insider Form 4s, and months of cash in the same pass.

The 8 Names

The biotech screener surfaces companies with clinical catalysts, insider conviction, deep drawdowns, and runway to execute. This week's top eight span pre-revenue gene editors, commercial-stage rare disease plays, and oncology franchises with protected moats. Analyst targets imply double-digit upside across the board, and insiders are stepping in while retail capitulates.

1. Ardelyx, Inc. (ARDX)

Stock Pixie Score 8.6/10 | 52-week drawdown: –28.9% | Analyst target: $16.10 (+169.5% upside) | 90% gross margin

The strongest composite signal on the board this week. ARDX carries an 8.6/10 Stock Pixie Score (a composite of valuation, income quality, and price recovery signals), a 90% gross margin, 22% revenue growth year-over-year, and a cash runway extending more than six years. The current ratio of 4.31 and minimal dilution (2.66% year-over-year) give management room to scale IBSRELA without constant equity raises.

CEO Michael Raab filed Form 4 transactions on February 25 and March 18, 2026. Net insider buying over six months totals 1,269,389 shares at an average of $6.08, a 26% buy-to-sell ratio by volume. Recent news highlights IBSRELA's 73% growth and management's reaffirmed $1 billion revenue target for 2029, with a Phase III program for chronic idiopathic constipation now in the pipeline.

The company remains unprofitable with a –24% return on invested capital. Until IBSRELA and future indications flip operating margins positive, cash burn remains the governor on the growth story.

2. Beam Therapeutics Inc. (BEAM)

Stock Pixie Score 7.1/10 | 52-week drawdown: –29.4% | Analyst target: $49.93 (+94.0% upside) | 120% revenue growth year-over-year

BEAM posted 120% revenue growth year-over-year and holds a current ratio of 13.09, giving the company 43 months of cash runway. The enterprise value to cash ratio of 1.20 means the market is valuing the entire platform at barely more than the balance sheet's liquid assets. Analysts maintain an 87.5% net bullish stance.

Giuseppe Ciaramella filed a Form 4 on February 26, 2026. Net insider buying over six months totals 1,206,855 shares at $10.00 per share, with a buy-to-sell ratio above 120% by volume. BEAM advanced BEAM-302 to pivotal stage with a 60 mg dose selection after hitting protective alpha-1 antitrypsin levels in AATD patients; the pivotal trial launches in H2 2026.

Return on invested capital is –261%, and dilution ran 22% year-over-year. Base editing promises transformative upside, but the company is burning capital to get there, and the path to profitability remains multi-year.

3. CRISPR Therapeutics AG (CRSP)

Stock Pixie Score 6.5/10 | 52-week drawdown: –34.0% | Analyst target: $84.78 (+63.6% upside) | 68.7-month cash runway

CRSP sits on nearly six years of cash runway with a current ratio of 13.32 and an enterprise value to cash ratio of 1.67. The market is pricing in modest premium to the balance sheet despite the company's stake in the first approved CRISPR gene therapy. Analysts hold a 61% net bullish view, and the drawdown zone flags a deep dip entry.

Revenue fell 100% year-over-year as commercialization of Casgevy (sickle cell disease and transfusion-dependent beta thalassemia) shifts to Vertex Pharmaceuticals under the partnership. CRSP's operating model now leans on royalties and milestone payments rather than direct sales, compressing near-term top-line visibility. Return on invested capital is –435%, and dilution is running 11.75% annually.

James Kasinger, Naimish Patel, and Samarth Kulkarni all filed Form 4s between March 12 and March 24, 2026. Net insider activity over six months is nearly flat at –261 shares, with buy and sell percentages each at 4.9%, signaling executive activity is dominated by option exercises and tax withholding rather than conviction buys.

The royalty stream from Casgevy is dependent on Vertex's commercial execution and payer dynamics in rare disease. If uptake stalls, CRSP's revenue model stalls with it.

4. Tempus AI, Inc. (TEM)

Stock Pixie Score 6.5/10 | 52-week drawdown: –49.5% | Analyst target: $77.93 (+47.8% upside) | 83% revenue growth year-over-year

TEM grew revenue 83% year-over-year and holds a 63% gross margin, anchoring a data-driven precision medicine platform that spans oncology and cardiology. The current ratio of 3.13 and 41.5-month cash runway provide execution cushion. Analysts are evenly split (50% net bullish), but the drawdown zone flags a deep dip.

Insiders are net sellers. Over six months, executives offloaded more than one million shares at an average price of $4.93, with a buy-to-sell ratio of 1% to 2.4% by volume. William Rogers and David Epstein both filed Form 4 sales in early March 2026. The enterprise value to cash ratio of 12.81 is the highest in this week's screen, and dilution ran 10% year-over-year.

TEM is pre-profitability with a –21% return on invested capital. The AI diagnostic and data aggregation model requires massive scale to reach unit economics that support the current valuation. If payer reimbursement tightens or hospital adoption slows, the path to cash flow positive extends.

5. Twist Bioscience Corporation (TWST)

Stock Pixie Score 6.4/10 | 52-week drawdown: –19.0% | Analyst target: $49.89 (+6.4% upside) | 51% gross margin

TWST posted 20% revenue growth year-over-year, maintains a 51% gross margin, and holds nearly 50 months of cash runway with a current ratio of 3.64. Dilution is contained at 3% year-over-year, and 80% of analysts maintain bullish ratings. The drawdown zone signals a strong entry.

Paula Green, Dennis Cho, and CEO Emily Leproust all filed Form 4 transactions between February 25 and March 24, 2026. Net insider buying over six months totals 368,440 shares at an average of $8.25, with a buy-to-sell ratio of 133% to 68% by volume. Twist recently added Invenra's bispecific platform to broaden its antibody discovery opportunity, expanding the total addressable market beyond synthetic DNA into therapeutic development.

Return on invested capital is –35%, and the enterprise value to cash ratio of 13.63 is the second-highest on this screen. The company remains unprofitable, and the analyst target implies only 6.4% upside, the lowest in the top eight.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Biotech stocks.

6. Regeneron Pharmaceuticals, Inc. (REGN)

Stock Pixie Score 6.1/10 | 52-week drawdown: –5.3% | Analyst target: $872.85 (+12.3% upside) | 21% return on invested capital

REGN is the only profitable company in this week's screen. Return on invested capital is 21%, the P/E sits at 18.75, and the 10-year normalized earnings yield is 0.97%, tight against the 10-year Treasury. The current ratio of 4.13 and enterprise value to cash ratio of 8.55 reflect a fortress balance sheet. Gross margin is 85%, and dilution is minimal at 1.16% year-over-year.

Arthur Ryan filed a Form 4 on March 3, 2026. Net insider buying over six months totals 457,101 shares at an average of $6.45, with a buy-to-sell ratio of 29.8% to 0.8% by volume. REGN secured Japan's first targeted bullous pemphigoid therapy approval, expanding its dermatology franchise, and the stock is up 28.9% over the past six months despite the broader biotech selloff.

Revenue growth is nearly flat at 1% year-over-year. The Eylea franchise faces biosimilar pressure, and the company's pipeline will need to deliver new blockbusters to sustain the current multiple. Analysts hold a 67% net bullish view, the lowest conviction reading among profitable names.

7. Emergent BioSolutions Inc. (EBS)

Stock Pixie Score 5.9/10 | 52-week drawdown: –40.6% | Analyst target: $12.00 (+43.7% upside) | 16% return on invested capital

EBS is profitable with a 16% return on invested capital, a P/E of 8.98, and a 10-year normalized earnings yield of 6.78%—well above the 10-year Treasury. The current ratio of 5.01 and enterprise value to cash ratio of 3.96 signal balance sheet strength. Dilution is negligible at 1.45% year-over-year, and analysts are 100% net bullish.

Coleen Glessner, Jessica Perl, and Joseph Papa all filed Form 4 transactions in early March 2026. Net insider activity over six months shows –48,191 shares, with a buy-to-sell ratio of 2.2% to 5.6% by volume, indicating tax-related selling rather than conviction buys. EBS secured over $60 million in new government contracts for smallpox medical countermeasures, backstopping near-term revenue.

Revenue fell 30% year-over-year as the company sheds non-core assets and exits unprofitable contracts. The gross margin of 54% is solid, but the top-line contraction raises questions about the durability of the government contracting backlog.

EBS is down 40.6% from its 52-week high, flagging a deep dip zone. If the contract pipeline dries up or biodefense budgets face cuts, the turnaround thesis breaks.

8. Exelixis, Inc. (EXEL)

Stock Pixie Score 5.8/10 | 52-week drawdown: –16.1% | Analyst target: $46.83 (+12.5% upside) | 68% return on invested capital

EXEL posted a 68% return on invested capital, the highest on this screen, with a P/E of 14.97 and a 10-year normalized earnings yield of 2.32%. The company is buying back shares, evidenced by –6.83% dilution year-over-year, and the current ratio of 3.56 signals balance sheet health. Revenue grew 7% year-over-year, and the gross margin is 96%.

Dana Aftab and CEO Michael Morrissey both filed Form 4 transactions between February 26 and March 2, 2026. Net insider buying over six months totals 2,157,881 shares at an average of $8.03, with a buy-to-sell ratio of 80.5% to 20% by volume. EXEL is advancing zanzalintinib in RCC trials and awaits a December PDUFA for CRC, with a label expansion for Cabometyx already in motion.

Analysts hold only a 55% net bullish view, the lowest conviction reading in the top eight. The enterprise value to cash ratio of 9.31 is elevated, and the analyst target implies only 12.5% upside. The market is pricing in limited pipeline optionality beyond Cabometyx line extensions.

What to Watch

BEAM's BEAM-302 pivotal trial initiation in H2 2026 for AATD will define whether the base editing platform can deliver a second commercial asset after sickle cell.
ARDX's chronic idiopathic constipation Phase III readout and IBSRELA's trajectory toward the $1 billion 2029 revenue target are the key de-risking events for the commercial franchise.
EXEL's December PDUFA for CRC and zanzalintinib RCC data drops will determine whether the oncology pipeline can offset Cabometyx biosimilar pressure.
REGN's Q1 2026 earnings on April 29, 2026, will clarify Eylea biosimilar impact and whether the Japan dermatology approval translates to material revenue.
EBS's ability to secure follow-on biodefense contracts beyond the $60 million smallpox award will validate or invalidate the turnaround thesis.

Go Deeper

The biotech screener surfaces names with clinical catalysts, insider conviction, and deep drawdowns where the market may be overreacting to sector fear. The top eight here represent the strongest composite signals this week, but Pro subscribers see the full ranked pipeline, including pre-clinical platforms, rare disease specialists, and diagnostic plays that didn't make this cut. Gene editors with pivotal trials launching, oncology franchises expanding labels, and commercial-stage rare disease companies with six-year runways are all in the dataset.

See all biotech picks →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full biotech screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.